Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Boston Scientific TAXUS VI stent data

In the European double-blind TAXUS VI trial in 448 patients at high risk of restenosis, the moderate-release formulation of BSX's

Read the full 201 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE